Improving the translational hit of experimental treatments in multiple sclerosis
Improving the translational hit of experimental treatments in multiple sclerosis
复制标题
DOI：
10.1177/1352458510379612
复制
发表时间：
2010-09-01
影响因子：
5.8
通讯作者：
Macleod, Malcolm R.
中科院分区：
文献类型：
--
作者：
Vesterinen, Hanna M.;Sena, Emily S.;Macleod, Malcolm R.
背景资料：在其他神经系统疾病中，未能将临床前发现转化为有效的临床治疗，部分归因于动物实验设计中的缺陷所引入的偏倚。Objectives：在这里，我们评估已发表的多发性硬化症动物模型干预研究的方法学设计和质量，并确定具有最佳疗效证据的候选干预措施。对描述在多发性硬化动物模型中测试干预措施有效性的实验的文献进行了系统综述。提取数据用于报告研究质量和设计以及神经行为结局。加权平均差异荟萃分析被用来提供药物的疗效，这是在五个或更多publications.Results报告的摘要估计：在临床前多发性硬化症模型中使用的药物在1152出版物，其中1117实验性自身免疫性脑脊髓炎（EAE）。对于36项更详细分析的干预措施，神经行为评分改善了39.6%（95%CI 34.9- 44.2%，p
Background: In other neurological diseases, the failure to translate pre-clinical findings to effective clinical treatments has been partially attributed to bias introduced by shortcomings in the design of animal experiments.Objectives: Here we evaluate published studies of interventions in animal models of multiple sclerosis for methodological design and quality and to identify candidate interventions with the best evidence of efficacy.Methods: A systematic review of the literature describing experiments testing the effectiveness of interventions in animal models of multiple sclerosis was carried out. Data were extracted for reported study quality and design and for neurobehavioural outcome. Weighted mean difference meta-analysis was used to provide summary estimates of the efficacy for drugs where this was reported in five or more publications.Results: The use of a drug in a pre-clinical multiple sclerosis model was reported in 1152 publications, of which 1117 were experimental autoimmune encephalomyelitis (EAE). For 36 interventions analysed in greater detail, neurobehavioural score was improved by 39.6% (95% CI 34.9-44.2%, p